CADTH | pCODR PAN-CANADIAN ONCOLOGY DRUG REVIEW

# PROVINCIAL FUNDING SUMMARY

## Bevacizumab (Avastin) for Cervical Cancer (pCODR 10045)

### pERC Recommendation: Recommends with conditions

For further details, please see pERC Final Recommendation

### Notification to Implement Issued by pCODR: April 8, 2015

This information is current as of December 3, 2018.

Note: Funding criteria as listed on the decision date. Please refer to the provincial drug programs for the most recent funding criteria and program eligibility.

| PROVINCE | STATUS | FUNDING DATE | FUNDING CRITERIA |
|---|---|---|---|
| BC | Funded | Apr 1, 2014 | For non-small cell cancer of the cervix (squamous); recurrent or IVb *ab initio* |
| AB | Funded | Dec 18, 2015 | Bevacizumab in combination with carboplatin and a taxane in the front line treatment of patients with advanced stage "high risk for progression" epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer that has good performance status. (High risk for progression defined as Stage III with > 1 cm of residual disease, Stage III unresectable or Stage IV). Dosing limited to 7.5 mg/kg. |
| SK | Funded | Dec 28, 2015 | In combination with platinum and Paclitaxel for the treatment of patients with metastatic (Stage IVb), persistent, or recurrent carcinoma of the cervix of all histologic subtypes, except small cell, and who have an ECOG performance status of 0 or 1. Bevacizumab is approved at a dose of 15 mg/kg for treatment until disease progression, unacceptable toxicity or complete response. |
| MB | Funded | Nov 16, 2015 | For the treatment of patients with: - Metastatic, persistent or recurrent cervical carcinoma AND - An Eastern Cooperative Oncology Group performance status of 0 or 1 AND - Adequate renal, hepatic and bone marrow function. |

| PROVINCE | STATUS | FUNDING DATE | FUNDING CRITERIA |
|---|---|---|---|
| ON | Funded | Jan 11, 2016 | In combination with chemotherapy for the treatment of patients with metastatic (Stage IVB), persistent, or recurrent carcinoma of the cervix of all histologic subtypes (except small cell); AND • Patient has ECOG ≤ 1 Dosing Regimen: 15mg/kg of body weight given once every 3 weeks as an intravenous infusion Notes: • On a time limited basis (6 months), o Patients who initiated first line chemotherapy prior to January 11, 2016 and whose disease has not progressed will have the option of adding bevacizumab. Patients who have achieved a clinically meaningful response on a first line chemotherapy regimen will have the option of adding bevacizumab when continuation of the same first line regimen is considered clinically appropriate • To be eligible for funding, patients must be able to start bevacizumab in combination with chemotherapy. • Funding will continue until disease progression. |
| NS | Funded | Feb 1, 2016 | In combination with chemotherapy for patients with metastatic (stage IVB), persistent or recurrent carcinoma of the cervix of all histologic subtypes (except small cell) and good performance status. Retreatment with bevacizumab plus chemotherapy may be offered to patients who have achieved a complete response (with previous bevacizumab and chemotherapy) and off treatment for at least 6 months. |
| NB | Funded | Dec 15, 2016 | In combination with platinum and paclitaxel chemotherapy for the treatment of patients with metastatic (stage IVB), persistent, or recurrent carcinoma of the cervix of all histologic subtypes (except small cell) and an ECOG performance status of 0 to 1. Retreatment with bevacizumab plus platinum and paclitaxel may be offered to patients following a complete response and a treatment-free period of at least 6 months. The funded dose is bevacizumab 15 mg/kg intravenously every 3 weeks until disease progression, unacceptable toxicity, or complete response, whichever occurs first. |
| NL | Funded | Nov 5, 2015 | In combination with chemotherapy for the treatment of patients with metastatic (Stage IVB), persistent, or recurrent carcinoma of the cervix of all histologic subtypes (except small cell) with an ECOG performance status ≤ 1 |

| PROVINCE | STATUS | FUNDING DATE | FUNDING CRITERIA |
|---|---|---|---|
| PEI | Funded | Aug 1, 2018 | In combination with chemotherapy for the treatment of patients with metastatic (stage IVB), persistent, or recurrent carcinoma of the cervix of all histologic subtypes (except small cell) and an ECOG performance status of 0 to 1. Retreatment with bevacizumab plus platinum and paclitaxel may be offered to patients following a complete response and a treatment-free period of at least 6 months. The funded dose is bevacizumab 15 mg/kg intravenously every 3 weeks until disease progression, unacceptable toxicity, or complete response, whichever occurs first. |